Sentinel lymph node mapping in early stage endometrial cancer.
Not Applicable
Not yet recruiting
- Conditions
- Endometrial cancer
- Registration Number
- ACTRN12618000958280
- Lead Sponsor
- Dept. Of Gynaecological Oncology Mater Adults Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- Female
- Target Recruitment
- 350
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does indocyanine green and near-infrared fluorescence imaging improve sentinel lymph node mapping accuracy in early-stage endometrial cancer?
What are the comparative outcomes of ICG/NIR sentinel lymph node mapping versus traditional lymphadenectomy in endometrial cancer?
Which molecular biomarkers predict successful sentinel lymph node identification using ICG in endometrial cancer patients?
What adverse events are associated with ICG-based sentinel lymph node mapping during minimally invasive endometrial cancer surgery?
How do combination approaches with ICG and other tracers enhance sentinel lymph node detection in endometrial cancer subtypes like endometrioid or serous?